Pacific Biosciences of California Inc (OQ:PACB)

Business Focus: Advanced Medical Equipment & Technology

Mar 27, 2024 08:00 am ET
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases
Mar 22, 2024 04:30 pm ET
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on March 18, 2024. The award was
Feb 26, 2024 03:05 pm ET
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Feb 15, 2024 03:05 pm ET
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
MENLO PARK, Calif., Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023.
Feb 13, 2024 06:00 am ET
Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch
ATLANTA, Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards. The award recognizes the outstanding use of technology to create an immersive and engaging event experience for PacBio (NASDAQ: PACB) a pioneering leader in the Biotechnology industry. The product launch at AEG's NOVO theater in Los Angeles announced two new genomic sequencing systems, Onso™ and Revio™.
Feb 05, 2024 08:05 am ET
PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale
New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System
Jan 25, 2024 03:03 pm ET
PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024
MENLO PARK, Calif., Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time.
Jan 15, 2024 08:05 am ET
PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions
Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria
Jan 08, 2024 07:00 am ET
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity
Dec 27, 2023 03:05 pm ET
PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT (4:30 PM ET) in San Francisco, California.
Dec 11, 2023 07:00 am ET
PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors
MENLO PARK, Calif., Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023.  
Nov 09, 2023 03:05 pm ET
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Nov 02, 2023 09:05 am ET
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders
Consortium Aims to Share Best Practices and Increase our Understanding of Genetic Disease
Nov 01, 2023 09:05 am ET
PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible
Partnerships Maximize Value of HiFi Data and Complete the Full End-to-End Workflow for PacBio Customers.
Oct 31, 2023 09:05 am ET
PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications
Building on the MAS-Seq Concatenation Method, These Three New Kits can Significantly Increase Throughput in RNA Applications
Oct 30, 2023 04:03 pm ET
PacBio Announces Third Quarter 2023 Financial Results
MENLO PARK, Calif., Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023.
Oct 16, 2023 08:05 am ET
PacBio Announces Appointment of David Meline to Board of Directors
Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board
Oct 12, 2023 04:03 pm ET
PacBio to Report Third Quarter 2023 Financial Results on October 30, 2023
MENLO PARK, Calif., Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023, at 4:30 pm Eastern Time.
Oct 11, 2023 09:05 am ET
PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis
PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis
Sep 12, 2023 08:00 am ET
PacBio Announces PacBio Capital
New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing  
Aug 07, 2023 08:00 am ET
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a research...
Jul 19, 2023 04:05 pm ET
PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023
MENLO PARK, Calif., July 19, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 5:00 pm Eastern Time.
Jun 28, 2023 07:00 am ET
PacBio's Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease
Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually
Jun 26, 2023 06:00 am ET
PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030
MENLO PARK, Calif., June 26, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. ("PacBio") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028 (the "2028 Notes"), pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 (the "New Notes") in exchange for $441 million principal amount of the 2028 Notes (the "Exchange Transaction"), in a transaction exempt from registration under the Securities Act of 1933,
May 30, 2023 09:05 am ET
May 25, 2023 04:03 pm ET
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., May 25, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences:
May 03, 2023 04:05 pm ET
PacBio to Present at BofA Securities 2023 Health Care Conference
MENLO PARK, Calif., May 3, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada.
May 02, 2023 04:01 pm ET
PacBio Announces Record Revenue in First Quarter 2023
MENLO PARK, Calif., May 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023.
Apr 18, 2023 04:05 pm ET
PacBio to Report First Quarter 2023 Financial Results on May 2, 2023
MENLO PARK, Calif., April 18, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time.
Apr 05, 2023 09:05 am ET
PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems
Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers
Mar 28, 2023 09:05 am ET
PacBio and Corteva Agriscience Enable Groundbreaking Plant and Microbial Long-Read Sequencing Workflow on Revio System
MENLO PARK, Calif., March 28, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced new workflows developed with global agriculture company, Corteva Agriscience that enable high throughput plant and microbial genome sequencing. This collaboration, which originated at the Advances in Genome Biology and Technology (AGBT) Agricultural meeting last year, delivers end-to-end workflows that streamline DNA extraction through library preparation, enabling Corteva to sequence thousands of samples annually, as part of the
Mar 14, 2023 09:05 am ET
PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes
Paraphase Enables Researchers to Analyze Genes That are Critically Relevant but Hard to Genotype
Feb 27, 2023 06:00 am ET
PacBio to Present at Cowen's 43rd Annual Health Care Conference
MENLO PARK, Calif., Feb. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts.
Feb 16, 2023 03:02 pm ET
PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
MENLO PARK, Calif., Feb. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2022.
Feb 07, 2023 08:05 am ET
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions
End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems
Feb 02, 2023 03:02 pm ET
PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023
MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.
Jan 24, 2023 10:18 pm ET
Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock
MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by PacBio. Before deducting the underwriting discount and estimated offering
Jan 24, 2023 03:05 pm ET
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock, at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be c
Jan 13, 2023 09:04 am ET
PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"
MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022." Nature Methods had recognized the impact of long-read sequencing in a variety of groundbreaking studies, including those leveraging PacBio technology from the Vertebrate Genome Project, Telomere-to-Telomere Consortium, and Human Pangeome Reference Consortium, among others.
Jan 09, 2023 06:05 am ET
PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022
PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program
Jan 09, 2023 06:00 am ET
PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration
MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo, Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.
Dec 28, 2022 03:05 pm ET
PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:
Dec 06, 2022 08:05 am ET
PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing
Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases
Nov 11, 2022 03:05 pm ET
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 11, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences:
Nov 07, 2022 03:05 pm ET
PacBio Announces Third Quarter 2022 Financial Results
MENLO PARK, Calif., Nov. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022.
Nov 02, 2022 09:05 am ET
PacBio Announces that Euan Ashley, M.D., Ph.D., Joseph Puglisi, Ph.D., and Jay Shendure, Ph.D., Join Newly Created Scientific Advisory Board
 World Class Team Will Provide Strategic Guidance and Direction for PacBio's Research and Development Activities
Oct 25, 2022 11:04 pm ET
PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000
Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revio to Dramatically Increase Throughput and Lower Cost While Leveraging the Power of HiFi for Exceptional Accuracy and Direct Methylation Detection
Oct 25, 2022 10:30 pm ET
PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform
The Onso Sequencing System is Designed to Deliver Industry-Leading Sensitivity and Specificity for Novel Insights in Oncology and Disease Research
Oct 25, 2022 10:29 pm ET
Oct 20, 2022 09:05 am ET
PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery
MAS-Seq Supports Isoform Research Using Single-Cell RNA Sequencing from 10x Genomics
Oct 19, 2022 09:05 am ET
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing
Alliance panels include a 50-gene pharmacogenomics panel and a nearly 400-gene panel of challenging, medically relevant "dark genes" developed in collaboration with leading institutions
Oct 18, 2022 09:05 am ET
PacBio Collaborates with Leading Researchers to Establish Long-Read Variant Frequency Consortium
The Consortium Will Build a Publicly Available Database as a Resource to Accelerate Insights from Long-Read Human Genome Datasets
Sep 27, 2022 09:05 am ET
PacBio Unveils a New Method for Comprehensive, Genome-wide Tandem Repeat Analysis
Analysis Method Supports Research on the Genetic Causes of Common Diseases
Sep 07, 2022 04:05 pm ET
PacBio to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.
Aug 19, 2022 04:05 pm ET
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., Aug. 19, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options covering an aggregate of 475,000 shares of PacBio common stock to the Company's recently hired Chief Commercial Officer, Jeff Eidel, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on August 16, 2022.
Aug 12, 2022 11:36 am ET
Thinking about buying stock in T2 Biosystems, Twin Vee Powercats, Rivian Automotive, DraftKings, or Pacific Biosciences of California?
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, VEEE, RIVN, DKNG, and PACB.
Aug 05, 2022 09:00 am ET
PacBio to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
MENLO PARK, Calif., Aug. 5, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.
Aug 03, 2022 04:05 pm ET
PacBio Announces Second Quarter 2022 Financial Results
MENLO PARK, Calif., Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022.
Jul 21, 2022 09:00 am ET
PacBio Announces Appointment of Genomics Industry Veteran Jeff Eidel as Chief Commercial Officer
MENLO PARK, Calif., July 21, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022. In this role, Mr. Eidel will have global responsibility for all commercial activity including sales, marketing, and customer support.
Jul 18, 2022 04:03 pm ET
PacBio to Report Second Quarter 2022 Financial Results on August 3, 2022
MENLO PARK, Calif., July 18, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2022 financial results on Wednesday, August 3, 2022, at 5:00 pm Eastern Time.
Jun 27, 2022 08:00 pm ET
PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of...
Jun 14, 2022 09:00 am ET
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been...
May 05, 2022 04:10 pm ET
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern...
May 04, 2022 04:03 pm ET
PacBio Announces First Quarter 2022 Financial Results
PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.Delivered a record 50 Sequel II/IIe...
Apr 21, 2022 09:10 am ET
PacBio and Children’s Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the...
Apr 21, 2022 09:00 am ET
PacBio transforms access to the epigenome and streamlines workflows
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s...
Apr 20, 2022 04:02 pm ET
PacBio to Report First Quarter 2022 Financial Results on May 4, 2022
PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at...
Apr 04, 2022 09:00 am ET
PacBio Enters Agricultural Industry Collaboration with Corteva Agriscience to Develop High-Throughput Plant, Pest and Microbial Sequencing
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, announced today a new collaboration with global agriculture company, Corteva Agriscience, to develop custom, end-to-end workflows for plant, pest and...
Mar 31, 2022 02:00 pm ET
HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, announced today PacBio’s essential contribution to the completion of the first truly complete human reference genome. The Telomere-to-Telomere (T2T)...
Mar 23, 2022 09:00 am ET
PacBio Opens European Headquarters in London
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, today announced the company’s expansion to better serve customers in the Europe, Middle East and Africa (EMEA) region. The company announced a new...
Feb 28, 2022 09:00 am ET
PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions
PacBio, a leading provider of high-quality, highly accurate sequencing platforms, today announced it will be supporting The Hospital for Sick Children (SickKids) in Toronto, Canada in using HiFi whole genome sequencing (HiFi WGS) to potentially...
Feb 25, 2022 05:00 pm ET
PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of...
Feb 23, 2022 09:00 am ET
PacBio Welcomes Dr. Michael Eberle as Vice President of Computational Biology
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology. Michael will be responsible for leading the company’s bioinformatics and...
Feb 16, 2022 09:00 am ET
KK Women’s and Children’s Hospital and PacBio Collaborate in Asia’s First Study of Unexplained Neurodevelopmental Disorders
KK Women’s and Children’s Hospital (KKH) and PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration to leverage PacBio technology in understanding the genetic causes of...
Feb 15, 2022 04:05 pm ET
PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results
PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release Achieved record fourth quarter revenues of $36.0 million reflecting growth of 33% compared to...
Feb 09, 2022 04:05 pm ET
PacBio to Present at Upcoming Investor Conferences
PacBio announced today that its executives will be speaking virtually at the following investor conferences: 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:00 pm Eastern Time (12:00 pm Pacific Time)Cowen 42nd...
Feb 01, 2022 04:05 pm ET
PacBio to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time. The call will be webcast live and may...
Jan 14, 2022 04:05 pm ET
PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000...
Jan 13, 2022 07:00 am ET
PacBio Names Lara Toerien as Vice President and General Manager for the Americas
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the company’s Americas region. Lara will be responsible for leading and...
Jan 11, 2022 09:45 am ET
Thinking about buying stock in Splash Beverage, TSR Inc, Phio Pharmaceuticals, Pacific Biosciences of California, or BioCryst Pharmaceuticals?
NEW YORK, Jan. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBEV, TSRI, PHIO, PACB, and BCRX.
Jan 11, 2022 07:15 am ET
PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, and Berry Genomics, a leading company in clinical genomics and life science in China, today announced a collaboration to provide PacBio long read...
Jan 11, 2022 07:10 am ET
PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics England to study PacBio’s technology for identifying genetic variants in unexplained rare disease cases....
Jan 11, 2022 07:05 am ET
PacBio and Google Collaborate to Use Machine Learning to Optimize Long-Read Sequencing Data Analysis
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced a research collaboration with Google. Under the terms of the collaboration, PacBio will explore the use of Google’s genomic analysis,...
Jan 11, 2022 07:00 am ET
PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company’s full...
Jan 07, 2022 09:00 am ET
Radboud University Medical Center Increases HiFi Sequencing Capacity with PacBio’s Sequel IIe
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands will increase their SMRT sequencing capacity with the...
Jan 06, 2022 09:00 am ET
Azenta Life Sciences Expands Fleet of PacBio HiFi Sequencing Systems
PacBio (Nasdaq: PACB) today announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio’s HiFi sequencing platforms across Azenta’s newly combined company and support...
Jan 05, 2022 09:00 am ET
PacBio and Care4Rare Consortium Collaborate on Rare Disease Research Study
PacBio, a leading provider of high-quality, long-read sequencing platforms, and the Care4Rare Canada Consortium (Care4Rare) announce today they are collaborating to study some of the most complex unexplained rare disease cases within Canada....
Jan 04, 2022 04:05 pm ET
PacBio to Present at Upcoming Investor Conference
PacBio announced today that its executives will be speaking virtually at the following investor conference: 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm Eastern Time (9:00 am Pacific Time) The live webcast can be...
Dec 28, 2021 09:00 am ET
PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants
PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced and captured the entire genome of the SARS-CoV-2...
Dec 07, 2021 09:00 am ET
PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseases
PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and the UCLA Institute for Precision Health and David Geffen School of Medicine at UCLA have formed a research collaboration to further identify the...
Dec 03, 2021 05:00 pm ET
PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000...
Nov 30, 2021 09:00 am ET
PacBio Names Jason Kang as Vice President and General Manager for Asia-Pacific Region
PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing platforms, welcomes Jason Kang as Vice President and General Manager for the company’s Asia-Pacific region. Jason will be responsible for leading and developing PacBio’s...
Nov 22, 2021 07:00 am ET
Organogenesis Appoints Prathyusha Duraibabu to Board of Directors
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 19, 2021 05:00 pm ET
PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000...
Nov 18, 2021 09:00 am ET
PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and ARUP Laboratories announced today they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be...
Nov 16, 2021 09:00 am ET
PacBio Launches HiFiViral SARS-CoV-2 Kit and Microbial Whole Genome Sequencing Enhancements to Combat Infectious Disease and Strengthen Public Health Response to Pathogen Threats
PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the launch of the HiFiViral SARS-CoV-2 Kit – a fully kitted end-to-end solution for COVID-19 surveillance, which public health...
Nov 11, 2021 04:05 pm ET
PacBio to Present at Upcoming Investor Conferences
PacBio announced today that its executives will be speaking at the following investor conferences: Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 am Eastern Time (8:20 am Pacific Time)Canaccord Genuity Virtual MedTech,...
Nov 03, 2021 09:31 am ET
Thinking about buying stock in PROG Holdings, Criteo SA, Pacific Biosciences, Allena Pharmaceuticals, or Intercept Pharmaceuticals?
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRG, CRTO, PACB, ALNA, and ICPT.
Nov 02, 2021 04:05 pm ET
PacBio Announces Third Quarter 2021 Financial Results
PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2021. Record revenue reflects 6th straight quarter of sequential growth Revenue of $34.9 million, an 83% increase compared with $19.1 million in the prior...
Nov 02, 2021 04:03 pm ET
PacBio’s Sequel IIe Selected by Prenetics to Build Personalized Genomics for Healthcare
PacBio will be providing its high-quality, highly accurate sequencing platforms to Prenetics Group Limited, a leading global genomics and diagnostic testing company, as the firm adds more comprehensive genetic screening services including carrier...
Oct 19, 2021 04:05 pm ET
Pacific Biosciences of California, Inc. Third Quarter 2021 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its third quarter 2021 financial results on Tuesday, November 2, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed...
Sep 27, 2021 09:00 am ET
PacBio Partners with The European Reference Genome Atlas Initiative
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, highly accurate sequencing platforms, today announced a partnership with The European Reference Genome Atlas (ERGA)...
Sep 24, 2021 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted...
Sep 20, 2021 04:05 pm ET
Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Omniome, a San Diego-based biotechnology company developing a proprietary and highly...
Sep 03, 2021 09:00 am ET
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Virtual Healthcare Conference on September 10, 2021, Fireside Chat at 12:40 pm Eastern...
Aug 09, 2021 08:00 am ET
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference
Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conference: UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, Panel Discussion at 4:00 pm...
Aug 03, 2021 04:05 pm ET
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue reflects continued quarter-over-quarter growth Revenue for the second quarter of 2021 was...
Aug 03, 2021 08:00 am ET
Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company
Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (“Circulomics”), a Maryland-based...
Jul 28, 2021 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted...
Jul 20, 2021 07:02 am ET
Pacific Biosciences and Invitae Announce Intent to Expand Collaboration
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced...
Jul 20, 2021 07:00 am ET
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome
Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced today that it has signed a definitive merger agreement under which it will...
Jul 19, 2021 04:05 pm ET
Pacific Biosciences of California, Inc. Second Quarter 2021 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at...
Jun 23, 2021 04:05 pm ET
Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit...
Jun 11, 2021 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted...
Jun 08, 2021 02:00 am ET
Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East, and Africa
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today welcomed Neil Ward to the new role of Vice President and General Manager for the company’s Europe, Middle East, and...
May 21, 2021 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the...
May 17, 2021 04:05 pm ET
Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Senior Vice President of Research
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced the appointment of three new hires to its growing team. Dr. Catherine Ball joins the company as Senior Vice...
May 04, 2021 09:00 am ET
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 2:00 p.m. EDT UBS...
Apr 29, 2021 04:05 pm ET
Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021. Record first quarter revenue reflects a strong start to 2021 Revenue for the first quarter of 2021 was $29.0 million,...
Apr 27, 2021 04:30 pm ET
Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr. Hannah Valantine has been nominated for election to the Company’s Board of Directors as a Class II...
Apr 26, 2021 08:00 am ET
Pacific Biosciences Launches New HiFi Sequencing Workflow to Further Improve HiFi’s Industry Leading Accuracy
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a global leader offering a comprehensive view of genomes, transcriptomes, and epigenomes, today announced the availability of HiFi Sequencing and Software v10.1 Release on the Sequel II and...
Apr 22, 2021 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the...
Apr 15, 2021 04:05 pm ET
Pacific Biosciences of California, Inc. First Quarter 2021 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results on Thursday, April 29, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at...
Mar 02, 2021 04:30 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Company’s Board of Directors granted...
Feb 26, 2021 04:04 pm ET
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Cowen Annual Health Care Conference on Monday, March 1, 2021 at 1:20 p.m. EST Barclays Global...
Feb 24, 2021 08:00 am ET
Children’s Mercy Kansas City Expands Investment in Pacific Biosciences Sequel IIe Systems to Scale Up Whole Genome Research Initiatives Focused on Rare Disease Diagnosis
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Children’s Mercy Kansas City, one of the nation’s top pediatric medical centers, has increased its...
Feb 18, 2021 08:01 am ET
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Labcorp (NYSE: LH), a leading global life sciences company, has increased its commitment to highly...
Feb 10, 2021 04:02 pm ET
Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company’s press release issued on January 11, 2021. Q4 2020...
Feb 10, 2021 08:00 am ET
Pacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today announced that SB Management, a subsidiary of Softbank Group Corp., will make an investment of $900...
Feb 05, 2021 05:00 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the...
Jan 29, 2021 04:15 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the...
Jan 27, 2021 02:30 pm ET
Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time. The call will be webcast and may be...
Jan 13, 2021 08:02 am ET
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to...
Jan 12, 2021 06:26 pm ET
Pacific Biosciences Grants Equity Incentive Awards to New Employees
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options...
Jan 11, 2021 07:45 am ET
Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue
Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31,...
Jan 08, 2021 08:45 am ET
Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both...
Jan 08, 2021 08:00 am ET
Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its...
Dec 18, 2020 04:05 pm ET
Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the...
Dec 16, 2020 08:00 am ET
SARS-CoV-2 Viral Genome Sequencing Data Presented from Research Using Pacific Biosciences Technology
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced initial findings from the company’s research collaboration with Labcorp that is focused...
Dec 14, 2020 08:00 am ET
Leading UK Core Labs Expand Investment in PacBio Sequencing Systems to Power Life Science Research with HiFi Reads
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that three of the United Kingdom’s leading core laboratories have increased their...
Nov 11, 2020 12:20 am ET
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a...
Nov 10, 2020 04:05 pm ET
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten...
Nov 02, 2020 04:02 pm ET
Pacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Third Quarter 2020 Financial Results Total revenue for the third quarter of 2020 was $19.1 million,...
Oct 22, 2020 08:00 am ET
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research...
Oct 19, 2020 12:30 pm ET
Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at...
Oct 15, 2020 08:00 am ET
Children’s Mercy Kansas City Teams Up with Pacific Biosciences to Fight Rare Disease
Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a...
Oct 05, 2020 08:00 am ET
Pacific Biosciences Launches the Sequel IIe System to Accelerate Adoption of Highly Accurate HiFi Sequencing
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the launch of the Sequel® IIe System, the next instrument evolution based on the...
Sep 14, 2020 09:00 am ET
Pacific Biosciences Announces New Chief Financial Officer
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September...
Aug 11, 2020 11:20 pm ET
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of 19,430,000 shares of its common stock at a price to the...
Aug 11, 2020 04:32 pm ET
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a...
Aug 07, 2020 08:30 am ET
Pacific Biosciences Announces New Chief Executive Officer
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Christian O. Henry as President and Chief Executive Officer,...
Aug 03, 2020 04:02 pm ET
Pacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Total revenue for the second quarter of 2020 was $17.1 million, compared with $24.6 million for the same period of...
Aug 03, 2020 08:05 am ET
Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced their clinical research collaboration aimed at developing molecular assays based on PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing technology. The initial focus of the collaboration will be on research in support of assay development for the carrier screening market.
Aug 03, 2020 08:00 am ET
Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in...
Jul 24, 2020 12:07 pm ET
Pacific Biosciences of California, Inc. Second Quarter 2020 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financial Results on Monday, August 3, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at...
Jun 10, 2020 08:59 am ET
Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by...
Jun 08, 2020 04:02 pm ET
Pacific Biosciences of California, Inc. Announces Rescheduling of 2020 Annual Meeting of Stockholders and Move to Virtual Meeting
The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling the date of the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) previously scheduled for...
May 06, 2020 04:03 pm ET
Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2020. As previously announced, in January 2020, we and Illumina mutually agreed to terminate the Agreement and Plan of...
Apr 27, 2020 01:09 pm ET
Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial Results on Wednesday, May 6, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at...
Apr 20, 2020 07:00 am ET
inqaba biotec acquires the first PacBio Sequel II System in Africa
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, and inqaba biotec, the leading commercial DNA sequencing service provider in sub-Saharan Africa, today...
Apr 08, 2020 07:30 am ET
Pacific Biosciences Powers SARS-CoV-2 Research at Commercial, Academic and Government Labs
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, academic and government research teams that are...
Mar 18, 2020 01:52 pm ET
Statement on Jury Verdict in Delaware Trial Against Oxford Nanopore Technologies
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall...
Mar 05, 2020 06:00 pm ET
Christian Henry Appointed Chairman of Pacific Biosciences’ Board of Directors
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its...
Feb 25, 2020 07:30 am ET
Pacific Biosciences to Support Sequencing of California Species for the Earth BioGenome Project
The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of...
Feb 07, 2020 04:03 pm ET
Pacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice...
Feb 06, 2020 04:02 pm ET
Pacific Biosciences Announces Fourth Quarter and Annual 2019 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31, 2019, as attached. Product, service and other revenue for the year ended December 31, 2019 increased by 16%...
Jan 21, 2020 02:16 pm ET
Pacific Biosciences of California, Inc. Fourth Quarter 2019 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Fourth Quarter 2019 Financial Results on Thursday, February 6, 2020, at 4:30pm Eastern Time. The Company will be sharing its plans for...
Jan 02, 2020 04:05 pm ET
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.
Nov 07, 2019 04:01 pm ET
Pacific Biosciences of California, Inc. Announces Third Quarter 2019 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company’) today announced financial results for its third quarter ended September 30, 2019. The Company has continued its commercial launch of the Sequel II System, which it began during...
Oct 10, 2019 07:30 am ET
Highly Accurate SMRT Sequencing for Human Genetics to Be Showcased at ASHG 2019 Annual Meeting
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that more than 50 presentations will include data from the company’s Single Molecule,...
Sep 05, 2019 07:30 am ET
European Research Initiative Adopts PacBio Sequel II System to Solve Rare Diseases
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that its Single Molecule, Real-Time (SMRT®) Sequencing technology has been selected by...
Aug 06, 2019 04:01 pm ET
Pacific Biosciences of California, Inc. Announces Second Quarter 2019 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2019. On April 24, 2019, the Company announced the commercial launch of the Sequel II System and the Single Molecule,...
Jun 13, 2019 07:30 am ET
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants
While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific...
May 03, 2019 04:01 pm ET
Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2019, as attached. During the first quarter of 2019, the Company announced that it commenced its Early Access Program of...
Apr 24, 2019 07:30 am ET
Pacific Biosciences Launches New Sequel II System, Featuring ~8 Times the DNA Sequencing Data Output
Pacific Biosciences of California Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the commercial launch of the Sequel® II System. The system includes the new SMRT® Cell...
Apr 02, 2019 07:30 am ET
Transplant Matches Identified by Ultra-High-Resolution HLA Typing Associated with Higher Patient Survival Rates
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that a retrospective study conducted by scientists at the Anthony Nolan Research...
Feb 26, 2019 07:30 am ET
Latest PacBio Sequencing Advancements Including Preview of Sequel II System to be Featured at Annual AGBT Conference
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced its participation in this week’s Advances in Genome Biology & Technology (AGBT)...
Feb 11, 2019 04:01 pm ET
Pacific Biosciences Announces Fourth Quarter and Annual 2018 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31, 2018, as attached. During the fourth quarter of 2018, the Company stated that it was targeting early access...
Jan 17, 2019 07:40 am ET
Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell — New Horizons, Emerging Trends,
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of SkyWest, Inc. (NASDAQ:SKYW), Pacific Biosciences of California, Inc....
Dec 31, 2018 10:51 am ET
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Red Hat, LSC Communications, Intersections, and Pacific Biosciences on Behalf of Stockholders and Enco
Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Red Hat, Inc., LSC Communications, Intersections Inc., and Pacific Biosciences of California, Inc.  Additional information about...
Dec 12, 2018 11:55 pm ET
Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Pac
Wolf Haldenstein Adler Freeman & Herz LLP  announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Pacific Biosciences of California, Inc. (“PACB”)...
Dec 10, 2018 05:06 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Pacific Biosciences of California, Inc. (PACB) on Behalf of Stockholders and Encourages PACB Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) on behalf of stockholders concerning the proposed acquisition of the company by Illumina, Inc....
Dec 07, 2018 02:04 pm ET
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS:
Dec 06, 2018 08:39 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Pacific Biosciences of California, Inc. - PACB
NEW YORK, Dec. 6, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of Pacific Biosciences of California, Inc. ("PACB" or the "Company") (NasdaqGS: PACB) for possible breaches of fiduciary duty related to the sale of the company to Illumnia, Inc. Under the terms of the proposed transaction, PACB shareholders are only anticipated to receive $8.00 in cash for each share of PACB common stock owned.
Nov 14, 2018 01:00 pm ET
PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito
Pacific Biosciences of California Inc., (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome...
Nov 07, 2018 07:45 am ET
Consolidated Research: 2018 Summary Expectations for Pacific Biosciences of California, NXP Semiconductors N.V., Consolidated Communications, Alexander & Baldwin, Willdan Group, and OneMain — Fundamen
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pacific Biosciences of California, Inc. (NASDAQ:PACB), NXP Semiconductors...
Nov 05, 2018 08:31 am ET
Thinking about buying stock in Apple, Aurora Cannabis Inc, Canadian Solar, Lowes or Pacific Biosciences?
NEW YORK, Nov. 5, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, ACB, CSIQ, LOW, and PACB.
Nov 01, 2018 04:15 pm ET
Pacific Biosciences of California, Inc. Announces Third Quarter 2018 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018. Total revenue for the third quarter of 2018 was $18.2 million, compared to $23.5 million for the third...
Nov 01, 2018 04:02 pm ET
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery
Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.
Oct 16, 2018 01:25 pm ET
Pacific Biosciences of California, Inc. Third Quarter 2018 Financial Results Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2018 Financial Results on Thursday, November 1, 2018, at 4:30pm Eastern Time. The call will be webcast and may be accessed...
Oct 15, 2018 07:30 am ET
PacBio Long-Read Sequencing Featured at ASHG Annual Meeting
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that more than 25 presentations at the upcoming American Society for Human Genetics...
Oct 10, 2018 08:50 am ET
Analysis: Positioning to Benefit within Air Products and Chemicals, Harsco, Pioneer Energy Services, Pacific Biosciences of California, Electronic Arts, and PriceSmart — Research Highlights Growth, Re
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Air Products and Chemicals, Inc. (NYSE:APD), Harsco Corporation...
Oct 10, 2018 07:30 am ET
Pacific Biosciences Announces a New Paradigm in DNA Sequencing – Highly Accurate Single-Molecule Long Reads
Significant Enhancements to Sequel System Enable >- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced major enhancements to its Sequel®...
Oct 08, 2018 07:30 am ET
Pacific Biosciences Releases Highest-Quality, Most Contiguous Individual Human Genome Assembly to Date
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced it has produced the most contiguous diploid human genome assembly of a single...
Sep 13, 2018 08:00 am ET
Large-Scale Global Genome Projects Choose PacBio Sequencing to Help Decode Life
When creating a genomic ark of creatures great and small, scientists across the globe are turning to the comprehensive coverage and quality of long-read sequencing technology from Pacific Biosciences (Nasdaq:PACB), the leading provider of...
Sep 12, 2018 12:10 am ET
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share....
Sep 10, 2018 04:01 pm ET
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a 30-day option to...
Aug 06, 2018 08:20 am ET
Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion, and Pacific Biosciences of California — What Drives Growth in Today's Competitive La
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allete, Inc. (NYSE:ALE), Sterling Construction Company Inc (NASDAQ:STRL),...
Aug 02, 2018 04:01 pm ET
Pacific Biosciences of California, Inc. Announces Second Quarter 2018 Financial Results
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2018. Total revenue for the second quarter of 2018 was $21.6 million, compared to $20.1 million for the second quarter...
Jul 31, 2018 09:15 am ET
Pacific Biosciences Appoints Christian Henry to Board of Directors
Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it has appointed industry veteran Christian Henry to its Board of Directors. Mr....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.